Paloma Partners’s Matinas BioPharma MTNB Stock Holding History

Paloma Partners’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-6,350	Closed	-$138K	–	1798
2018 Q2	$138K	Buy	6,350 +6,002	+1,725%	+$173K	﹤0.01%	1513
2018 Q1	$13K	Hold	348	–	–	﹤0.01%	1880
2017 Q4	$20K	Buy	+348	New	+$22.4K	﹤0.01%	1831

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

KJHP

K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Paloma Partners's MTNB Position: Q3 2018 in Review

Paloma Partners sold out of Matinas BioPharma (MTNB) in Q3 2018, closing a stake of 6,350 shares — an estimated $138K sold.

Paloma Partners first reported a position in MTNB in Q4 2017 and held it in 3 quarters. The position peaked at $138K in Q2 2018. 31 funds tracked by Wall St. Rank hold MTNB as of Q3 2018.

Paloma Partners reported no remaining Matinas BioPharma position as of Q3 2018 after selling out during the quarter.
Paloma Partners sold 6,350 Matinas BioPharma shares in Q3 2018, an estimated $138K.
Paloma Partners first reported a position in Matinas BioPharma in Q4 2017 and held it in 3 quarters.
Paloma Partners's Matinas BioPharma position peaked at $138K in Q2 2018.
31 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2018.

Based on Paloma Partners's 13F filing for Q3 2018, filed 14 Nov 2018.